Natural History Study of Blood Cancers Including Monoclonal B Cell Lymphocytosis, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Lymphoplasmacytic Lymphoma, Waldenstrom Macroglobulinemia, and Splenic Marginal Zone Lymphoma

What this Trial Is About

Researchers are studying the natural history of monoclonal B cell lymphocytosis MBL, chronic lymphocytic leukemiasmall lymphocytic lymphoma CLLSLL, lymphoplasmacytic lymphoma LPLWaldenstrom macroglobulinemia WM, and splenic marginal zone lymphoma SMZL. The study aims to understand the molecular and clinical aspects of these related blood cancers before and after treatment, using new technologies to explore disease progression and identify potential treatment targets. Participants diagnosed with these conditions will be followed regularly, typically every 6 to 12 months for the first two years and then every 12 to 24 months afterwards. They may undergo blood draws, biopsies, and imaging tests such as PET, CT, and MRI scans. While no treatment is given in this study, patients requiring therapy will be referred to appropriate clinical trials or treatment options outside this study. During the study, participants provide clinical information and biological samples for research. They are monitored through periodic clinic visits and testing to track disease stability and progression. The main measurement is treatment-free survival, which assesses time until active disease requires treatment. This ongoing observational study helps advance understanding and future therapies for these blood cancers.

Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL)